Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) EBT: 2019-2024

Historic EBT for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to -$261.9 million.

  • Kymera Therapeutics' EBT fell 28.31% to -$92.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$332.6 million, marking a year-over-year decrease of 65.94%. This contributed to the annual value of -$261.9 million for FY2024, which is 58.02% down from last year.
  • As of FY2024, Kymera Therapeutics' EBT stood at -$261.9 million, which was down 58.02% from -$165.7 million recorded in FY2023.
  • Over the past 5 years, Kymera Therapeutics' EBT peaked at -$46.4 million during FY2020, and registered a low of -$261.9 million during FY2024.
  • Its 3-year average for EBT is -$196.3 million, with a median of -$165.7 million in 2023.
  • Data for Kymera Therapeutics' EBT shows a maximum YoY tumbled of 116.95% (in 2021) over the last 5 years.
  • Over the past 5 years, Kymera Therapeutics' EBT (Yearly) stood at -$46.4 million in 2020, then slumped by 116.95% to -$100.7 million in 2021, then tumbled by 60.30% to -$161.4 million in 2022, then decreased by 2.66% to -$165.7 million in 2023, then tumbled by 58.02% to -$261.9 million in 2024.